At a Glance
Regime: Bounce · Open: Gap up · Risk on new positions: High · Custom T2108: 45.2, flat
Focus: DCTH (Earnings Catalyst · Duration) · VIR (Biotech Catalyst · Duration)
Secondary: N/A
Tonight After Hours: ABCL, BETR, FWRD, JRVR, PUBM, RLGT, ZYME · Tomorrow Before Open: HBIO, JRSH, LEGN, ONON, WIX
Holding: N/A
Situational Awareness
Market Condition: Bounce
Commentary: We're still in a poor market. I'm just going through my process each day. Focusing solely on catalysts. Reduced timeframe for any trades. I went to cash last week as the market broke down.
Not a lot of faith in general here. Will continue to be defensive. Less (or nothing!) is the way to do things here. Keep the account near the highs so that you don't have to stage a recovery when the market comes around again.
Using the time for new studies and reviews.
Two picks today that would be solid in any other market. Skeptical on them today but they're good setups. Situational Awareness reduced the likelihood of follow through.
Not listed - NVDA is a short that many people will be looking at but I am wary of Trump or someone else coming out defending and minimizing that Huang honeypot headline.
Today In Focus
DCTH — Delcath Systems: Delcath Systems Reports Third Quarter 2026 Results and Business Highlights
Earnings Catalyst · Duration · Mkt cap $518.1M · Float 32M · SI 5.9% (6.2 days) · Nasdaq · Theme: Medical - Devices · Next earnings N/A
Why: Strong earnings report, Solid 35% Revs Beat. Accelerating YoY revs, EPS Beat, Strong KPIs, Raised Guidance on headlines and HEPZATO KPI + Gross Margins.
Level: $18.50 · U&R $18
DCTH daily · trigger $18.50 · U&R $18
VIR — Vir Biotechnology: Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data
Biotech Catalyst · Duration · Mkt cap $2.1B · Float 131M · SI 12.4% (6.9 days) · Nasdaq · Theme: Biotechnology · Next earnings N/A
Why: Strong Phase 3 Data for Chronic Hepatitis. Success was expected but it definitely outdid expectation. Good chart and the drug seems to be far superior for patients than Gilead's currently approved one. It's under VWAP Pre Market. Want it to be strong out the gate to have any chance.
Level: $15
VIR daily · trigger $15
Trade Updates
CASH
Macro Events (Eastern Time)
Monday November 9 2026
No scheduled data of note.
Fed Speakers: Bowman 8:40 AM, Goolsbee 10:00 AM, Barkin 12:15 PM
IPOs Today
N/A
Biotech Calendar
XBI -2.42% on the week and +1.96% on the month, under its 50-day.
Today: N/A
Coming up: Tue 10 Nov · KPTI (Karyopharm Therapeutics Inc.) · PDUFA · Thu 12 Nov · NERV (Minerva Neurosciences, Inc.) · Readout
Note: Never front-run biotech catalysts. Wait for the catalyst to hit, then assess if the reaction is tradable. Dates are estimates and can shift.
Full H2 Biotech Watchlist: TradingView
Have a Great Day!
Sean Sharpe
